| Date | Title | Description |
| 12.03.2025 | Pierre Fabre Laboratories and RedRidge Bio Announce a Drug Discovery and Co-development Partnership | CASTRES, France, CAMBRIDGE, Massachusetts and BASEL, Switzerland, March 12, 2025 /PRNewswire/ -- Pierre Fabre Laboratories and RedRidge Bio ("RedRidge") today announced an exclusive R&D collaboration and license agreement to i... |
| 13.02.2025 | Helicore Biopharma: $65 Million (Series A) Raised For Glucose-Dependent Insulinotropic Peptide Platform | Helicore Biopharma, a biopharmaceutical company focused on discovering and developing first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists for obesity and related conditions, announced its emergence from stealth mode wi... |
| 22.11.2024 | KMS Technology Receives Investment from Sunstone Partners | KMS Technology, an Atlanta, GA-based provider of digital engineering, data and AI services, received an investment from Sunstone Partners.
The amount of the deal was not disclosed.
The company intends to use the funds to accelerate its cont... |
| 28.10.2024 | Monte-Rosa Therapeutics enters billion-dollar partnership with Novartis |
Monte Rosa Therapeutics is a clinical-stage biotechnology company based in Boston and Basel developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune ... |
| 24.10.2024 | Jade Biosciences Extends Financing; Total To $95M | Jade Biosciences, a Vancouver, BC, Canada-based biotechnology company dedicated to developing therapies for patients living with autoimmune diseases, extended its financing, bringing the total raised to $95M.
The round added Frazier Life Sc... |
| 21.10.2024 | Bright Peak Therapeutics enters the clinic with first immunotherapy for cancer |
Using innovative protein engineering and a proprietary chemical protein synthesis and conjugation platform, Bright Peak is developing a pipeline of first-in-class multifunctional molecules. The company’s lead program, BPT567, is designed t... |
| 17.06.2024 | Bright Peak Therapeutics raises USD90 million to advance lead program into clinical trials |
Bright Peak Therapeutics is a biotechnology company advancing a portfolio of multifunctional immunotherapies to treat cancer and other diseases. “We are now well positioned to bring much needed innovation to the field of anti-PD-1 immune-c... |
| 10.05.2024 | Capsida Biotherapeutics to Present Preclinical Data for Parkinson's Disease Associated with GBA Mutations Showing High Levels of GCase Enzyme Supplementation Following IV Administration | Next-generation gene therapy demonstrates best-in-class potential with majority of neurons transduced in substantia nigra and high levels of GCase supplementation after single IV infusion
Broad GCase elevation achieved in NHPs, while signif... |
| 03.04.2024 | From generative chemistry to computational astrophysics, startups employ new methods to fight cancer | Here are a few startups in the cancer space that made headlines recently
The recent revelation of Princess Kate Middleton’s battle with cancer has sent ripples across the globe, reminding us that this disease knows no boundaries of status o... |
| 18.03.2024 | With MS & Fibrosis Trials Planned, J&J-Partnered Contineum Now Preps for IPO | Johnson & Johnson is a partner on Contineum Therapeutics’ most advanced program, which is currently in mid-stage clinical testing for multiple sclerosis. As that research continues and Contineum plans to advance the development of its w... |
| 14.11.2023 | Nouscom raises CHF65 million in oversubscribed Series C financing round | |
| 18.09.2023 | French pharma giant acquires Basel based Vertical Bio | |
| 12.09.2023 | Pierre Fabre Laboratories Acquires Vertical Bio and its Innovative Targeted Therapy Candidate for Patients Suffering From Non-Small Cell Lung Cancer With MET Alteration | CASTRES, France and BASEL, Switzerland, Sept. 12, 2023 /PRNewswire/ -- Pierre Fabre Laboratories, the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio AG, a developer of novel cancer therapies. Thi... |
| 12.08.2022 | Vector BioPharma becomes operational with $30 million series A | |
| 13.04.2022 | Newly launched biotech banks CHF46 million | |
| 13.04.2022 | Versant Ventures Launches Cimeio Therapeutics with $50 Million Series A | - |
| 09.09.2021 | Lycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant Ventures | - |
| 09.09.2021 | Lycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant Ventures | -- Advancing novel targeted therapeutics using its LYTAC protein degradation technology --
-- Plans to use $105 million in recent capital, including $35 million upfront payment from strategic collaboration with Lilly, to progress internal p... |
| 14.06.2021 | Bright Peak Therapeutics Closes $107 Million Financing Round | |
| 21.04.2021 | Versant Ventures Raises $950 Million Across Three Vehicles | - |
| 21.04.2021 | Versant Ventures raises $950M to fund biotech bets | (Kwanchai Lerttanapunyaporn/Getty Images)
Biotech investor Versant Ventures has raised $950 million across three funds to fuel a strategy that prioritizes building new companies from scratch.
Versant VIII, a $560 million fund, will seed the... |
| 21.04.2021 | Versant Ventures : Raises $950 Million Across Three Vehicles | Versant Ventures today announced $950 million in additional capital allocated across a platform of three separate vehicles. These included Versant Venture Capital VIII, a $560 million primary global biotech fund; Versant Voyageurs II, a $14... |
| 21.04.2021 | Versant nets $950M to build its next class of biotech startups | Versant Ventures banked $950 million in its latest raise to invest in 20 or more biotech startups and chip into later-stage rounds for its portfolio companies.
RELATED: Foresite banks $969M to back companies tackling healthcare challenges h... |
| 19.10.2020 | VectivBio secures $110 million to finance Phase III clinical trials | |
| 19.10.2020 | VectivBio secures $110 million to finance Phase III clinical trials | VectivBio closed a $110 million crossover financing from new investors Surveyor Capital (a Citadel company), Cormorant Capital and Eventide Asset Management, with participation from existing investors Versant Ventures, OrbiMed, Novo Holding... |
| 29.07.2020 | Bright Peak off to a good start with $35 million from Versant Ventures | |
| 29.07.2020 | Bright Peak off to a good start with $35 million from Versant Ventures | Bright Peak Therapeutics launched out of Versant Ventures’ Ridgeline Therapeutics Discovery Engine based in Basel, to focus on the development of a technology platform, licensed from ETH Zürich, which allows a wide range of proteins to be c... |
| 09.06.2020 |
Versant Ventures Launches New Company, Lycia Therapeutics, With $50M
| San Diego-based venture investor Versant Ventures has launched a brand new company out of its Inception Discovery Engine incubator in San Diego, saying this morning it has invested $50M in Lycia Therapeutics. According to Versant Ventures, ... |
| 09.06.2020 | Versant Ventures Launches Lycia Therapeutics with $50 Million | - |
| 09.01.2020 | Therachon spin-off launches with $35 million investment | |
| 09.01.2020 | Therachon spin-off launches with $35 million investment | VectivBio, a clinical-stage biotechnology company, is bringing transformational medicines to patients with serious rare diseases. The company announced its formation with $35 million in financing including commitments by Versant Ventures, O... |
| 14.10.2019 | Top 10 VCs investing in medical device companies | They include NEA, Versant Ventures, SOSV and Innova Memphis
Healthtech is a big and broad space, so much so that there are whole subsectors that see more investments than entire industries.
Medical device companies, for example, raised $2.9... |
| 13.09.2019 | Anokion raises $40 million and acquires US biotech startup | |
| 04.09.2019 | Versant Ventures launches medtech fund Vensana with $225m | Versant Ventures said today that it completed the closing of the Vensana Capital fund, a venture capital and growth equity investment firm dedicated to the medtech sector with more than $200 million in committed capital.
Vensana Capital int... |
| 04.09.2019 | Versant's Repare raises $82M to trial synthetic lethality drugs | Repare Therapeutics has raised an $82.5 million series B round to take synthetic lethality drugs into humans. The Versant Ventures-founded biotech plans to start testing ATR inhibitor RP-3500 in the clinic next year while putting a second a... |
| 04.06.2019 | Northleaf closes $300 million VCCI-backed Venture Catalyst Fund II | Northleaf Capital Partners has announced the final close of its Northleaf Venture Catalyst Fund II, meeting its cap target and bringing the fund to $300 million,
“We are excited to continue to support the development and evolution of the Ca... |
| 08.05.2019 | Pfizer Acquires Therachon for up to $810 million | |
| 10.01.2019 | Versant’s Black Diamond raises $85M, plots transatlantic move | Versant Ventures’ Black Diamond Therapeutics has raised $85 million (€74 million). The series B, which comes weeks after Black Diamond exited stealth mode, tees the allosteric oncogenic mutation specialist up to move two or three candidates... |
| 17.12.2018 | Versant Ventures Raises $700M for Two Funds | Versant Ventures, a healthcare investment firm, closed two funds, totalling $700m.
This included:
– Versant Venture Capital VII, a $600m primary biotech fund, and
– Versant Voyageurs I, a $100m Canadian companion fund.
Both funds exceeded t... |
| 17.12.2018 | Top startup news for today, Monday, December 17 | Good morning! Here are some of the top technology startup news stories for today, Monday, December 17.
Tech startup Toast bags $115 million to simply work for restaurant owners. Toast, an all-in-one restaurant technology platform, has rais... |
| 17.12.2018 | Versant Ventures Raises $700 Million | SAN FRANCISCO & NEW YORK & VANCOUVER, British Columbia & BASEL, Switzerland--(BUSINESS WIRE)--Versant Ventures today announced an infusion of $700 million through two new funds. These include a primary global fund, Versant Ventu... |
| 17.12.2018 | Silicon Valley’s Versant raises $134 mln to help fill Canada’s biotech VC gap | - |
| 17.12.2018 | Versant raises $100M for new Canada fund on top of $600M for global biotech startups | In addition, Versant raised $100 million for Versant Voyageurs I, a Canadian companion fund whose aim is to provide capital to between five to eight startup companies with Canadian operations. Like Fund VII, Voyageurs I also exceeded its ta... |
| 17.12.2018 | Versant Ventures Raises USD100 Million Canadian Fund | - |
| 17.12.2018 | Versant Ventures Raises $700 Million | - |
| 17.12.2018 | Versant closes two new biotech funds totaling $700M
W h i t e p a p e r
Weighing the Costs: | Versant Ventures unveiled a pair of new funds—a $600 million global biotech fund, its seventh, and a $100 million companion fund that will focus on startups in Canada. The new funds, dubbed Versant Venture Capital VII and Versant Voyageurs ... |
| 12.12.2018 | Black Diamond Therapeutics Raises $20M Series A | BASEL, Switzerland & TORONTO–(BUSINESS WIRE)–Black Diamond Therapeutics, a biotechnology company developing a new type of precision medicine for cancer, came out of stealth mode today with a $20 million Series A financing exclusively fr... |
| 11.12.2018 | Versant launches Black Diamond Therapeutics with $20M to pursue untapped cancer mutations | While in stealth mode, Versant said, Black Diamond built and established proof of concept for its MAP platform, whose name stands for mutation, allostery and pharmacology. The platform is designed to find and target allosteric mutant oncoge... |
| 15.09.2018 | 40 AND UNDER: The Silicon Valley biotech stars who are backing startups aiming to cure disease, prolong life, and fix the food system | This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Putting millions of dollars into bold new technologies can be a delicate business when lives hang in the balance. But every day some of the... |
| 09.08.2018 | Therachon Raises $60 Million Mezzanine Financing | |
| 25.06.2018 | Akero Therapeutics Closes $65 Million Series A | Akero Therapeutics, Inc., a biotechnology company focused on transforming the treatment of non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases, today announced the completion of a $65 million Series A financing. The fi... |
| 14.03.2018 | Gute Aussichten für Basler Startups | |
| 06.11.2017 | 5AM Ventures Joins 42M Euros Series B for NousCom | NousCom, an oncology company developing neoantigen based cancer vaccines based on its Exovax platform, today announced the completion of a €42 million Series B financing. The round involved a syndicate of leading transatlantic life sciences... |
| 06.11.2017 | Versant Ventures Joins 42M Euros Series B for NousCom | NousCom, an oncology company developing neoantigen based cancer vaccines based on its Exovax platform, today announced the completion of a €42 million Series B financing. The round involved a syndicate of leading transatlantic life sciences... |
| 15.02.2017 | Versant finishes Fund V with $20M NASH startup | As far as startups go, the bet looks relatively safe. Jecure’s executive team is proven and familiar. CEO Jeffrey Stafford and CSO James Veal led the team at Quanticel Pharmaceuticals, a 2010 genomics startup hand-raised by Versant.
Celgene... |
| 02.02.2017 | Vividion Therapeutics Raises $50M in Series A Financing | Vividion Therapeutics, a San Diego, CA-based biotechnology company, raised $50M in Series A financing.
Founding investors are ARCH Venture Partners and Versant Ventures. In conjunction with the financing, Tom Daniel, M.D., Executive Chairma... |
| 02.02.2017 | Versant Ventures Leads $30 Million Series D for Tarveda Therapeutics | WATERTOWN, Mass.--(BUSINESS WIRE)--Tarveda Therapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing Pentarins™ as a new class of potent and selective cancer medicines, today announced the completion of a $30... |
| 09.01.2017 | Therachon Closes Series A Financing and Appoints new CEO | |
| 06.01.2017 | Term Sheet — Friday, January 6 | CES, CMO, IPO, CAIO
Unicorn Watch: Yesterday I interviewed Xiaomi CFO Shou Zi Chew, formerly a partner at DST Global. Xiaomi, valued at $45 billion, is at CES hoping to deliver on its promise of a broad tech ecosystem offering a variety of ... |
| 05.01.2017 | Healthcare Venture Capital Firm Versant Ventures Strengthens Investment Team | In preparation for the launch of its new $400M fund, global healthcare venture capital firm Versant Ventures announced several appointments to its Investment Team.
In details, Clare Ozawa, Ph.D., will transition from her current role as Chi... |
| 04.01.2017 | Term Sheet — Wednesday, January 4 | DELL-EMC, NYC EXITS, HYPEMOBILES
Hello from Las Vegas, where I’m riding in cars with robots and hunting down the most ridiculous “smart” items CES has to offer. (Current front-runners: a smart mattress and a smart hairbrush.)
Paid Content S... |
| 03.01.2017 | Versant Ventures Raises $400M for Sixth Fund | SAN FRANCISCO & VANCOUVER, British Columbia & NEW YORK & BASEL, Switzerland--(BUSINESS WIRE)--Versant Ventures today announced the close of its newest fund, Versant Venture Capital VI, at its hard cap of $400 million. Versant wi... |
| 03.01.2017 | Healthcare Investment Firm Versant Ventures Closes Fund, at $400M | Global healthcare investment firm Versant Ventures closed of its newest fund, at $400m.
Versant Venture Capital VI, supported by existing and new limited partners, will use its strategy to find, form and fund innovative healthcare companies... |
| 06.11.2016 | Versant Ventures Raises $350M for Sixth Fund | Versant Ventures is seeking to raise $350 million for its sixth fund, according to an SEC filing. In 2015, the healthcare-focused investment firm closed its fifth fund at $305 million. |
| 17.05.2016 | New company of former Okairos founders bags €12 million | |
| 12.04.2016 | Versant Ventures Announces Promotions and Additions | Versant Ventures, a global healthcare venture capital firm, announced promotions and an addition to its investment team, as well as appointments at its discovery engines in Toronto and New York City.
In details, Versant promoted Jerel Davis... |
| 09.03.2016 | Daily funding roundup - March 9, 2016 | Catalyst DevWorks raised $11.5M; Omnes led investment in Intersec; Drive Spotter secured $750k
Drive Spotter, a video analytics platform for commercial fleets, secured $750,000 in seed financing led by Grinnell Mutual Reinsurance Company wi... |
| 11.12.2015 | Kyras Therapeutics Closes Series A Financing | Kyras Therapeutics, Inc., a NYC-based biotech company, closed a Series A financing of undisclosed amount.
The round was led by Versant Ventures. As part of the financing, Brad Bolzon, Managing Director at Versant Ventures, and Carlo Rizzuto... |
| 28.10.2015 | Daily funding roundup - October 28, 2015 | Alteryx bagged $85M; Paddle8 secured $34M; Personal Genome raised $21.4M
A new startup called Localize wants to help companies outsource their international efforts. Specifically, Localize helps translate apps and websites into other langua... |
| 28.10.2015 | Turnstone Biologics Completes $11.3M Series A Financing Round | Turnstone Biologics Inc., a Toronto, Ontario, Canada-based developer of novel oncolytic viral immunotherapies, completed an $11.3m Series A financing round.
The round was led by Versant Ventures with follow-on capital committed in excess of... |
| 01.10.2015 | Daily funding roundup - October 1, 2015 | General Assembly raised $70M; Neon Therapeutics secured $55M; Dolly landed $8M
Social Finance (SoFi for short), a lending startup has raised a monster round of funding, taking $1 billion from SoftBank, with existing Third Point Ventures and... |
| 24.08.2015 | Versant Ventures Launches NYC-based Biotech Incubator Highline Therapeutics | Versant Ventures, a global healthcare venture capital firm, launched its third biotech incubator, Highline Therapeutics.
The firm also promoted Carlo Rizzuto as Venture Partner to manage its newly established New York base. Rizzuto, who joi... |
| 30.04.2015 | CRISPR Therapeutics Raises Additional $64 Million | |
| 10.12.2014 | Versant Ventures Closes Fifth Healthcare Fund at $305M | Versant Ventures, a global healthcare investment firm, closed its fifth fund at $305m.
Versant Venture Capital V L.P. will continue to invest in innovative biopharmaceutical, medical device, and healthcare services/HCIT companies.
The portf... |
| 10.12.2014 | Versant Ventures closes new $305 mln fund with help of Canadian LPs | - |
| 20.10.2014 | Daily funding roundup - October 20, 2015 | Yidao Yongche bagged $700M; Gritstone Oncology raised $102M; Zignal Labs landed $15M
Zignal Labs, a realtime cross media analytics company, today announced the completion of a $15 million round of funding. The round was led by existing inve... |
| 25.06.2014 | Northleaf Venture Catalyst Fund Commits $10M to Versant Ventures to Support Life Sciences Startups | Northleaf Venture Catalyst Fund* has committed $10m to global healthcare venture capital manager Versant Ventures to support investment in Canada’s early-stage life sciences industry.
Founded in 1999 and led by Brad Bolzon, PhD., Managing D... |
| 18.06.2014 | Benvenue Medical secures $40M Series E to beef up manufacturing, U.S. commercialization | InterWest Partners led the round, and general partner Dr. Gil Kliman was appointed to Benvenue’s board. Other investors include DeNovo Ventures, Domain Associates, Technology Partners and Versant Ventures. Silicon Valley Bank was the sole d... |
| 09.05.2014 | Anokion Closes $37.5M Series A Financing Round | Anokion SA, a Lausanne, Swuitzerland-based developer of a technology for retraining white blood cells to induce therapeutic immune tolerance, closed a CHF33m (approximately $37.5m) Series A financing round.
The round was co-led by Novartis ... |
| 05.05.2014 | Swiss biotech start-up Anokion closes financing round for CHF 33 Million | |
| 24.04.2014 | Crispr Therapeutics Raises $25M in Series A Funding | Crispr Therapeutics, a Basel, Switzerland-based biopharmaceutical company that focuses on the gene-editing technology CRISPR-Cas9, raised $25m in Series A funding.
Versant Ventures made the investment.
The company intends to use the funds t... |
| 16.04.2014 | ForSight VISION5 Completes $15M Series C Financing | ForSight VISION5, a Menlo Park, CA-based developer of non-invasive products to replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy, completed a $15m Series C finan... |
| 15.04.2014 | AAVLife Raises $12M in Series A Financing | AAVLife, a Paris, France-based gene-therapy company focusing on rare diseases, raised $12m in Series A financing.
The round was led by Versant Ventures, with participation from Inserm Transfert Initiative, a French seed-investment firm link... |
| 08.04.2014 | Versant Ventures invests CHF 11 million in PIQUR | |
| 09.12.2013 | US-based biotech VC opens Vancouver office, puts $10 million into first deal here | Article content
A California-based venture capital firm specializing in life sciences, with more than $1.6 billion in assets under management, has targeted British Columbia for investment, opening an office here and investing $10 million in... |
| 09.12.2013 | San Francisco’s Versant Ventures Makes Splash in Vancouver; $10 Million to Biotech Company | San Francisco and Menlo Park-based US venture capital firm Versant Ventures is “venturing” up north.
The life sciences venture capital firm is building a presence in British Columbia so it can invest in early-stage drug discovery companies ... |
| 24.10.2013 | Versant Ventures is raising $250M for medtech VC | Medical device investment group Versant Ventures is looking to raise a new $250 million fund, the group’s 5th fund so far.
The funding round should be a short one, although the 1st sale has yet to occur, according to regulatory filings. The... |
| 23.10.2013 | Versant Ventures seeks $250M for next medtech venture capital fund | Directors who will manage the fund listed on the regulatory filing include CFO Robin Praeger; Bradley Bolzon, formerly of Roche and Eli Lilly; VV Co-Founder Samuel Colella; VV Co-Founder Dr. Ross Jaffe, formerly of Brentwood Venture Capital... |
| 16.10.2013 | Inceptus Medical Completes $4.7M Series A financing for Inari Medical | Inceptus Medical, LLC, an Aliso Viejo, CA-based medical device company incubator, completed a $4.7m Series A financing for its first new company, Inari Medical Inc.
The financing will provide the resources to develop and commercialize innov... |
| 08.08.2013 | Stanford spinoff goes data-mining for a better diagnostic for preeclampsia | Carmenta’s test combines computational algorithms with novel protein biomarkers in serum to identify at-risk pregnant mothers. It’s described this way in a February announcement from the company:
The underlying technology for the test was d... |
| 15.07.2013 |
Versant Ventures Names Mazzo Operating Partner
| Newport Beach-based venture capital investor Versant Ventures has named former Advanced Medical Optics CEO Jim Mazzo as an Operating Partner. According to Versant Ventures, Mazzo will focus on patient needs, new technology advancements and ... |
| 29.05.2013 | GSK acquires Okairos AG for EUR 250 mio | |
| 08.05.2013 | Three examples of how “the system” is changing medtech investment decisions | Neilsen’s comment was one of two that showed how governments, C-suite executives and payers are guiding investment decisions in the medtech world.
Josh Baltzell of Split Rock Partners said that one of his portfolio companies is selling into... |
| 08.05.2013 | Medtech investors explain the nuances of evaluating reimbursement risk | Kirk Nielsen of Versant Ventures said that when Versant invests, they consider the possibility that with early stage companies, it may be an acquirer who fights the reimbursement fight.
“We need to be prepared to take it all the way, but we... |
| 25.03.2013 | Novira Therapeutics Secures $7.5M; Completes $25M Series A Financing | Novira Therapeutics, Inc., a Radnor, PA-based antiviral drug discovery company, secured $7.5m and completed its $25m Series A financing.
New investor Versant Ventures joined 5AM Ventures and Canaan Partners, which led the first closing of t... |
| 25.03.2013 | Biotechnology company adds new investor in its fight against Hepatitis B virus | In an e-mail to clarify the financing, Chief Scientific Officer and President Osvaldo Flores said the financing round followed a two-step closing model in which investors 5AM and Canaan led the first closing in August with a partial syndica... |
| 29.11.2012 | CardiAQ Valve Technologies Receives $37.3M in Second Equity financing | CardiAQ Valve Technologies, Inc., an Irvine, Calif.-based medical device company developing technologies for percutaneous mitral heart valve replacement, has received $37.3m in its second equity financing.
The round was led by OrbiMed, with... |
| 12.11.2012 | Device startup aims to bring implantable solution to the problem of central sleep apnea | This novel therapy is meant to prove better clinical outcomes than the standard treatments, which include CPAP masks, drugs and other types of airflow devices.
Labosky said that data from a feasibility study showed that the remede device is... |
| 12.09.2012 | Fundraising: Startup developing nonsurgical treatment for urinary incontinence raises $3.9M | Solution/product: The Renessa System uses a probe guided through the urethra and radio frequency energy to treat female stress urinary incontinence in lieu of surgical treatments. The product has been cleared by the U.S. Food and Drug Admin... |
| 06.08.2012 | Respicardia Receives $6M Senior Credit Facility from Ares Capital Corporation | Respicardia, Inc., a near Minneapolis, Minnesota-based early stage company developing a medical device targeted to improve respiratory and cardiovascular health by treating central sleep apnea, has received a $6m senior secured credit facil... |
